Last reviewed · How we verify

NCT05093569: GLAM

Clinical Investigation of K'Watch - Lab & Home Study

Status unknown Last updated 2 May 2022
What this trial tests

trial testing K'watch in Diabetes in 35 participants. Status unknown.

Timeline
15 November 2021
Primary endpoint
30 December 2022
30 December 2022

Quick facts

Lead sponsorPKvitality
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment35
Start date15 November 2021
Primary completion30 December 2022
Estimated completion30 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

PKvitality

Who can join

Adults 18 to 80, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study categorized as a non significant risk trial is a monocentric, prospective, open-label comparative, paired-design trial aims to evaluate the performance and the tolerance of K'Watch CGM system in comparison with conventional reference (YSI system, BGM system and CGM systems ) . This trial will be conducted on patients with Type 1 and 2 of diabetes for 8 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05093569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing